相关实验视频
Updated: Jan 16, 2026

10:43
Evaluating In Vitro DNA Damage Using Comet Assay
Published on: October 11, 2017
39.4K
在固体瘤中使用PARP抑制剂的静脉血栓栓塞事件风险:系统性审查和元分析
S C Yazgan1, E Yekedüz2, E Akkuş1
1Department of Medical Oncology, Ankara University School of Medicine, Ankara, Turkey; Ankara University Cancer Research Institute, Ankara, Turkey.
ESMO open
|September 30, 2025
概括
多 (ADP-ribose) 聚合酶抑制剂 (PARPi) 可能会增加癌症患者静脉血栓栓塞事件 (VTE) 的风险. 这种风险在前列腺癌和胰腺癌中似乎更高,因此需要仔细考虑PARPi的使用.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 血液学 血液学 血液学
背景情况:
- 多 (ADP-ribose) 聚合酶抑制剂 (PARPi) 是用于癌症治疗的一类药物.
- 已知PARPi的副作用是血栓事件的风险增加.
- 用PARPi治疗的不同癌症类型中静脉血栓栓塞事件 (VTE) 的特定风险尚未确定.
研究的目的:
- 评估PARPi治疗的实体瘤患者中VTE的发生率和风险.
- 在各种癌症亚型中比较与PARPi相关的VTE风险.
主要方法:
- 随机对照II期和III期临床试验的元分析.
- 包括前列腺,乳腺,卵巢,胰腺,质母细胞瘤,SCLC和NSCLC癌症的患者.
- 评估PARPi治疗患者与对照患者的静脉瘤发作频率和风险.
主要成果:
- 分析了38项研究中的15008名患者.
- 任何级别的VTE的发生率为2.4%与PARPi相比,对照组的1.6% (OR1.37,P=0.050).
- 在前列腺 (OR 1.98) 和胰腺 (OR 7.22) 癌症患者中观察到明显更高的VTE风险.
结论:
- 使用PARPi与潜在的VTE风险增加有关,特别是在前列腺癌和胰腺癌等特定癌症类型中.
- 对VTE风险的PARPi单一治疗的整体贡献可能是有限的.
- 由于研究异质性和缺乏患者级数据,研究结果应谨慎解释.
相关概念视频
Venous Thrombosis III: Interprofessional Care
280
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
280
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.1K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.1K
Venous Thrombosis I: Introduction
373
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
373
mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Tumor Progression
7.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.2K

